{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:24:41Z","timestamp":1769811881943,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.ejim.2010.03.010","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T09:12:13Z","timestamp":1271322733000},"page":"254-259","source":"Crossref","is-referenced-by-count":8,"title":["Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes"],"prefix":"10.1016","volume":"21","author":[{"given":"Pier Mannuccio","family":"Mannucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2010.03.010_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ejim.2009.09.005","article-title":"New antiplatelet agents: why they are needed","volume":"20","author":"Franchini","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ejim.2009.05.004","article-title":"A new era for anticoagulants","volume":"20","author":"Franchini","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM199807233390407","article-title":"Hemostatic drugs","volume":"339","author":"Mannucci","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib4","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMra067742","article-title":"Prevention and treatment of major blood loss","volume":"356","author":"Mannucci","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib5","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.03.010_bib6","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2010.03.010_bib7","doi-asserted-by":"crossref","first-page":"34C","DOI":"10.1016\/j.amjcard.2009.06.013","article-title":"Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction","volume":"104","author":"Willis","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2010.03.010_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.03.010_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2459\/JCM.0b013e3283299808","article-title":"Clinical implications and management of bleeding events in patients with acute coronary syndromes","volume":"10","author":"De Luca","year":"2009","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2010.03.010_bib11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehm019","article-title":"Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Rao","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2010.03.010_bib12","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/CIRCULATIONAHA.107.694273","article-title":"Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?","volume":"116","author":"Spencer","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.03.010_bib13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2007.10.042","article-title":"Percutaneous coronary intervention pharmacology: from a triangle to a square","volume":"51","author":"Dauerman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2010.03.010_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","article-title":"Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes","volume":"292","author":"Rao","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2010.03.010_bib15","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/01.CIR.0000162477.70955.5F","article-title":"Association of hemoglobin levels with clinical outcomes in acute coronary syndromes","volume":"111","author":"Sabatine","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.03.010_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004303","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","volume":"2","author":"Hill","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2010.03.010_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-116-5-393","article-title":"Prudent strategies for elective red blood cell transfusion","volume":"116","author":"Welch","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMoa070403","article-title":"Duration of red-cell storage and complications after cardiac surgery","volume":"358","author":"Koch","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib19","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1161\/01.CIR.97.6.562","article-title":"Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial","volume":"97","author":"van de Watering","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.03.010_bib20","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1161\/01.CIR.0000130162.11925.21","article-title":"Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery","volume":"109","author":"Bilgin","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.03.010_bib21","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2008-10-167643","article-title":"Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention","volume":"113","author":"Vamvakas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2010.03.010_bib22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"issue":"Suppl. 6","key":"10.1016\/j.ejim.2010.03.010_bib23","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2010.03.010_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.292.1.45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2010.03.010_bib25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib26","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib27","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1600-0609.1965.tb01300.x","article-title":"Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid","volume":"2","author":"Andersson","year":"1965","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.ejim.2010.03.010_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0005-2795(75)90216-0","article-title":"Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids","volume":"393","author":"Thorsen","year":"1975","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejim.2010.03.010_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003602","article-title":"Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion","volume":"1","author":"Henry","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2010.03.010_bib31","first-page":"479","article-title":"Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs","volume":"33","author":"Fritz","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejim.2010.03.010_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4615-9546-5_6","article-title":"Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo","volume":"247B","author":"Hoffmann","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ejim.2010.03.010_bib33","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa0802395","article-title":"A comparison of aprotinin and lysine analogues in high-risk cardiac surgery","volume":"358","author":"Fergusson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1503\/cmaj.081109","article-title":"The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis","volume":"180","author":"Henry","year":"2009","journal-title":"CMAJ"},{"issue":"S1","key":"10.1016\/j.ejim.2010.03.010_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2516.2007.01608.x","article-title":"The use of desmopressin in open-heart surgery","volume":"14","author":"Cattaneo","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejim.2010.03.010_bib36","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1055\/s-0038-1649883","article-title":"The effect of desmopressin on reducing blood loss in cardiac surgery \u2014 a meta-analysis of double-blind, placebo-controlled trials","volume":"74","author":"Cattaneo","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2010.03.010_bib37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/0003-4975(94)91636-5","article-title":"Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding","volume":"58","author":"Fremes","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejim.2010.03.010_bib38","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(99)01264-7","article-title":"Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints","volume":"354","author":"Levi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.03.010_bib39","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2010.03.010_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V99.3.923","article-title":"Mechanism of factor VIIa-dependent coagulation in hemophilia blood","volume":"99","author":"Butenas","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2010.03.010_bib41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1172\/JCI116691","article-title":"The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor","volume":"92","author":"ten Cate","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2010.03.010_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V99.1.175","article-title":"Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A","volume":"99","author":"Lisman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2010.03.010_bib43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.CCM.0000159087.85970.38","article-title":"Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review","volume":"33","author":"Levi","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ejim.2010.03.010_bib44","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1538-7836.2006.02088.x","article-title":"Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation","volume":"4","author":"Altman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2010.03.010_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tmrv.2007.03.003","article-title":"The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders","volume":"21","author":"Poon","year":"2007","journal-title":"Transfus Med Rev"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:17:47Z","timestamp":1711401467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620510000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0953620510000531"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2010.03.010","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}